Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  ImmunoGen, Inc.    IMGN

Delayed Quote. Delayed  - 07/22 10:00:00 pm
2.85 USD   --.--%
07/21 IMMUNOGEN, INC. : Announces Conference Call to Discuss Its Fourth Qu..
06/15 IMMUNOGEN : Announces Pricing of $100 Million Offering of 4.50% Conv..
06/13 IMMUNOGEN : Announces Proposed $100 Million Offering of Convertible ..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Income Statement Evolution
Annual Income Statement Data
Actuals in M $ Estimates in M $
Fiscal Period June 201320142015201620172018
Sales35,559,985,569,263,882,1
Operating income (EBITDA)-68,4-66,9-54,4-114-125-126
Operating profit (EBIT)-73,0-71,5-59,9-113-131-118
Pre-Tax Profit (EBT)-72,8-----
Net income-72,8-71,4-60,7-131-153-142
P/E ratio-19,1-14,3-20,3-1,88-1,75-1,95
EPS ( $ )-0,87-0,83-0,71-1,52-1,63-1,46
Dividend per Share ( $ )------
Yield------
Reference price ( $ )16.5911.8514.382.852.852.85
Announcement Date08/02/2013
10:30am
08/01/2014
10:30am
07/31/2015
10:30am
---
Finances - Leverage
Actuals in M $ Estimates in M $
Fiscal Period June 201320142015201620172018
Debt---19,212398,7
Finance195142278---
Operating income (EBITDA)-68,4-66,9-54,4-114-125-126
Leverage
(Debt/EBITDA)
----0,17x-0,99x-0,78x
Capital Expenditure3,778,187,4315,216,617,5
Book Value Per Share (BVPS)1,44 $0,88 $0,41 $-0,85 $-2,01 $-1,70 $
Cash Flow per Share-0,72 $-0,63 $-0,64 $-1,32 $--
Announcement Date08/02/2013
10:30am
08/01/2014
10:30am
07/31/2015
10:30am
---
Balance Sheet Analysis
Assessed data source :
© 2016 Thomson Reuters
Advertisement
Financial Ratios

Size 2016e 2017e
Capitalization 248 M$ -
Entreprise Value (EV) 267 M$ 371 M$
Valuation 2016e 2017e
P/E ratio (Price / EPS)
Capitalization / Revenue 3,59x 3,89x
EV / Revenue 3,86x 5,82x
EV / EBITDA -2,34x -2,98x
Yield (DPS / Price) - -
Price to book (Price / BVPS) -3,35x -1,42x
Profitability 2016e 2017e
Operating Margin (EBIT / Sales) -163% -206%
operating Leverage (Delta EBIT / Delta Sales) -4,63x -2,05x
Net Margin (Net Profit / Revenue) -190% -240%
ROA (Net Profit / Asset) -53,0% -
ROE (Net Profit / Equities) 2 183% -
Rate of Dividend - -
Balance Sheet Analysis 2016e 2017e
CAPEX / Sales   22,0% 26,1%
Cash Flow / Sales -166% -
Capital Intensity (Assets / Sales) 3,58x -
Financial Leverage (Net Debt / EBITDA) -0,17x -0,99x
Price Earning Ratio Help 
The blue ligne is the average P/E ratio (without estimates)
EPS & Dividend